These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 12810627

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Thymocyte expression of cathepsin L is essential for NKT cell development.
    Honey K, Benlagha K, Beers C, Forbush K, Teyton L, Kleijmeer MJ, Rudensky AY, Bendelac A.
    Nat Immunol; 2002 Nov; 3(11):1069-74. PubMed ID: 12368909
    [Abstract] [Full Text] [Related]

  • 23. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
    Søndergaard H, Coquet JM, Uldrich AP, McLaughlin N, Godfrey DI, Sivakumar PV, Skak K, Smyth MJ.
    J Immunol; 2009 Dec 01; 183(11):7326-36. PubMed ID: 19915059
    [Abstract] [Full Text] [Related]

  • 24. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K, Leggatt GR, Zhong J, Liu X, de Kluyver RL, Peters T, Fernando GJ, Liem A, Lambert PF, Frazer IH.
    J Natl Cancer Inst; 2004 Nov 03; 96(21):1611-9. PubMed ID: 15523090
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Treatment of subcutaneous tumor with adoptively transferred T cells.
    Peng L, Shu S, Krauss JC.
    Cell Immunol; 1997 May 25; 178(1):24-32. PubMed ID: 9184695
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
    Braza MS, Klein B.
    Br J Haematol; 2013 Jan 25; 160(2):123-32. PubMed ID: 23061882
    [Abstract] [Full Text] [Related]

  • 33. Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.
    Mokyr MB, Prokhorova A, Rubin M, Bluestone JA.
    J Immunol; 1994 Oct 01; 153(7):3123-34. PubMed ID: 8089490
    [Abstract] [Full Text] [Related]

  • 34. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
    Schirrmann T, Pecher G.
    Cancer Gene Ther; 2002 Apr 01; 9(4):390-8. PubMed ID: 11960290
    [Abstract] [Full Text] [Related]

  • 35. Characterization of the phenotype and function of CD8(+), alpha / beta(+) NKT cells from tumor-bearing mice that show a natural killer cell activity and lyse multiple tumor targets.
    Stremmel C, Exley M, Balk S, Hohenberger W, Kuchroo VK.
    Eur J Immunol; 2001 Sep 01; 31(9):2818-28. PubMed ID: 11536181
    [Abstract] [Full Text] [Related]

  • 36. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
    Cohen PA, Peng L, Kjaergaard J, Plautz GE, Finke JH, Koski GK, Czerniecki BJ, Shu S.
    Crit Rev Immunol; 2001 Sep 01; 21(1-3):215-48. PubMed ID: 11642606
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.